GTCR to sell Antylia Scientific’s Masterflex unit in $2.9bn deal, two years after buyout | AltAssets Private Equity News
US private equity major GTCR‘s Antylia Scientific portfolio company has agreed to sell its Masterflex business unit to trade buyer Avantor for $2.9bn in an all-cash transaction. GTCR picked up Antylia two years ago, and said it had made significant investments in its products and commercial infrastructure, as well as completing two strategic add-on acquisitions in its life sciences business unit. Never miss a story – click to sign up to AltAssets’ free daily PE newsletter Masterflex specialises in peristaltic and single-use bioprocessing solutions, including peristaltic pumps, tubing, flow meters and single-use components and assemblies. GTCR and other shareholders will continue to own Antylia and its remaining assets following the Masterflex sale, including its portfolio of life sciences products. Last year GTCR reached a $7.5bn target-beating final close for its thirteenth flagship buyout fund after just five months of fundraising.
Governance, risk and compliance
HSE- Health, Safety and Environment
Medical Equipment Software